Equities analysts expect that SAGE Therapeutics Inc (NASDAQ:SAGE) will report earnings of ($2.04) per share for the current quarter, Zacks reports. Zero analysts have made estimates for SAGE Therapeutics’ earnings, with estimates ranging from ($2.35) to ($1.79). SAGE Therapeutics reported earnings of ($1.50) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 36%. The firm is expected to report its next quarterly earnings report on Thursday, February 22nd.

On average, analysts expect that SAGE Therapeutics will report full year earnings of ($7.42) per share for the current fiscal year, with EPS estimates ranging from ($7.73) to ($7.16). For the next fiscal year, analysts forecast that the business will post earnings of ($7.69) per share, with EPS estimates ranging from ($9.08) to ($6.43). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that cover SAGE Therapeutics.

SAGE Therapeutics (NASDAQ:SAGE) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.98) by $0.01. The firm’s revenue for the quarter was up .0% compared to the same quarter last year.

SAGE has been the subject of a number of recent research reports. Royal Bank of Canada increased their target price on SAGE Therapeutics from $117.00 to $120.00 in a report on Thursday, November 2nd. Leerink Swann increased their target price on SAGE Therapeutics from $123.00 to $246.00 in a report on Thursday, December 7th. Goldman Sachs Group reissued a “buy” rating and issued a $87.00 target price on shares of SAGE Therapeutics in a report on Friday, October 6th. Needham & Company LLC dropped their target price on SAGE Therapeutics from $95.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday, September 13th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $91.00 target price (down from $104.00) on shares of SAGE Therapeutics in a report on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $171.21.

Shares of SAGE Therapeutics (NASDAQ SAGE) traded down $2.95 on Friday, hitting $161.37. The stock had a trading volume of 344,500 shares, compared to its average volume of 607,061. SAGE Therapeutics has a fifty-two week low of $44.55 and a fifty-two week high of $173.36.

In related news, insider Albert Robichaud sold 60,000 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the sale, the insider now directly owns 152,759 shares in the company, valued at approximately $24,354,367.37. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.10% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. boosted its position in SAGE Therapeutics by 5.9% in the 2nd quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock valued at $241,431,000 after buying an additional 168,424 shares during the last quarter. Vanguard Group Inc. boosted its position in SAGE Therapeutics by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 2,749,954 shares of the biopharmaceutical company’s stock valued at $219,006,000 after buying an additional 58,679 shares during the last quarter. Bank of New York Mellon Corp boosted its position in SAGE Therapeutics by 36.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock valued at $168,834,000 after buying an additional 724,494 shares during the last quarter. State Street Corp boosted its position in SAGE Therapeutics by 7.7% in the 2nd quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock valued at $96,558,000 after buying an additional 87,097 shares during the last quarter. Finally, Oak Ridge Investments LLC boosted its position in SAGE Therapeutics by 0.9% in the 3rd quarter. Oak Ridge Investments LLC now owns 736,709 shares of the biopharmaceutical company’s stock valued at $45,897,000 after buying an additional 6,835 shares during the last quarter. Hedge funds and other institutional investors own 95.33% of the company’s stock.

WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/12/20/brokerages-expect-sage-therapeutics-inc-sage-will-announce-earnings-of-2-04-per-share.html.

SAGE Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Get a free copy of the Zacks research report on SAGE Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.